Evercore trims Quest target

Evercore ISI just cut its Quest Diagnostics target to $210 from $220 and kept an “In Line” rating, which is analyst language for “not bad enough to downgrade, not good enough to get excited.” The change came on April 8, one day after Quest shares closed near $198, so the new target still points to only modest upside. (trendonify.com) Quest Diagnostics is the company behind a huge share of routine bloodwork, cancer screening support, and employer testing in the United States, so Wall Street watches it like a tollbooth business: small price changes on millions of tests can move profits fast. Quest said full-year 2025 revenue reached $11.04 billion, up 11.8% from 2024. (questdiagnostics.com) The company also told investors on February 10 that 2026 revenue should land between $11.70 billion and $11.82 billion, with adjusted diluted earnings per share between $10.50 and $10.70. That is growth, but it is not the kind of jump that lets analysts ignore every pressure point in the business. (questdiagnostics.com) Those pressure points are mostly boring, expensive things: labor, transportation, supplies, and what insurers and government programs will pay for each test. In a lab business, a penny shaved off reimbursement can hit like a supermarket cutting the price of milk after you already paid for the trucks, fridges, and staff. (questdiagnostics.com) That is why a $10 target cut gets attention even without a rating change. Evercore itself had raised its Quest target to $220 from $190 on February 11, so this April move reverses part of that optimism less than two months later. (gurufocus.com 1) (gurufocus.com 2) Quest is not being treated like a company in trouble. Across analysts tracked in one recent roundup, the median target sat around $215, with most ratings clustered in hold-style categories rather than outright buy or sell calls. (trendonify.com) So the message from this note is narrower than “Quest is weak.” It is closer to “the stock already reflects a lot of the good news,” even after Quest posted fourth-quarter 2025 revenue of $2.81 billion and raised its quarterly dividend 7.5% to $0.86 per share. (questdiagnostics.com) For anyone who runs or invests in labs, this is the part to watch: public markets are still rewarding steady execution, but they are not handing out rich valuations just because test volumes are stable again. When a company with $11 billion in annual revenue gets a target trimmed while guidance stays intact, investors are saying the margin story still needs proof. (questdiagnostics.com) (trendonify.com)